Lake Street analyst Thomas Flaten adjusted the firm’s price target on Checkpoint Therapeutics to $41 from $70 to reflect the recent reverse stock split and capital raise and keeps a Buy rating on the shares, noting that he values cosibelimab at $33 per share and olafertinib at $8 per share. Checkpoint "achieved a significant milestone" with the submission of a BLA for cosibelimab for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma, said Flaten, who expects a PDUFA date in early 2024, assuming the FDA does not raise any issues.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CKPT:
- Checkpoint filing starts ‘transformative shift,’ says H.C. Wainwright
- Checkpoint Therapeutics’ BLA submission positive news, says Cantor Fitzgerald
- Checkpoint Therapeutics submits BLA to FDA for cosibelimab
- Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
- Checkpoint price target adjusted to $76 at H.C. Wainwright after reverse split